Influenza vaccination and Guillain Barre syndrome.
Acute and severe Guillain Barre Syndrome (GBS) cases reported following influenza vaccine to the Vaccine Adverse Events Reporting System (VAERS) database from 1991 through 1999 were examined. Endotoxin concentrations were measured using the Limulus amebocyte lysate assay in influenza vaccines. There were a total of 382 cases of GBS reported to the VAERS database following influenza vaccination (male/female ratio, 1.2). The median onset of GBS following influenza vaccine was 12 days (interquartile range, 7 days to 21 days). There was an increased risk of acute GBS (relative risk, 4.3; 95% confidence interval, 3.0 to 6.4) and severe GBS (relative risk, 8.5; 95% confidence interval, 3.7 to 18.9) in comparison to an adult tetanus-diphtheria (Td) vaccine control group. There were maximums in the incidence of GBS following influenza vaccine that occurred approximately every third year (1993, 1996, and 1998) and statistically significant variation in the incidence of GBS among different influenza manufacturers. Influenza vaccines contained from a 125- to a 1250-fold increase in endotoxin concentrations in comparison to an adult Td vaccine control and endotoxin concentrations varied up to 10-fold among different lots and manufacturers of influenza vaccine. The biologic mechanism for GBS following influenza vaccine may involve the synergistic effects of endotoxin and vaccine-induced autoimmunity. There were minimal potential reporting biases in the data reported to the VAERS database in this study. Patients should make an informed consent decision on whether to take this optional vaccine based upon its safety and efficacy and physicians should vigilantly report GBS following influenza vaccination to the VAERS in the United States so that continued evaluation of the safety of influenza vaccine may be undertaken.
Geier
Mark R
MR
The Genetic Centers of America, 14 Redgate Court, Silver Spring, MD 20905, USA. mgeier@erols.com <mgeier@erols.com>
Geier
David A
DA
Zahalsky
Arthur C
AC
D000293:Adolescent; D000328:Adult; D016907:Adverse Drug Reaction Reporting Systems; D002487:Centers for Disease Control and Prevention, U.S.; D022422:Diphtheria-Tetanus Vaccine / Q000009:adverse effects; D004731:Endotoxins / Q000009:adverse effects / Q000032:analysis; D005260:Female; D020275:Guillain-Barre Syndrome / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D015994:Incidence; D007252:Influenza Vaccines / Q000009:adverse effects* / Q000032:analysis; D007251:Influenza, Human / Q000517:prevention & control; D008033:Limulus Test; D008297:Male; D008875:Middle Aged; D009975:Orthomyxoviridae / Q000276:immunology; D011358:Product Surveillance, Postmarketing; D012306:Risk; D014481:United States / Q000453:epidemiology
D022422:Diphtheria-Tetanus Vaccine; D004731:Endotoxins; D007252:Influenza Vaccines